Female Sex and Bronchioloalveolar Pathologic Subtype Predict EGFR Mutations in Non-small Cell Lung Cancer

Hsieh, Ruey‐Kuen; Lim, Ken-Hong; Kuo, Hsu-Tah; Tzen, Chin‐Yuan; Huang, Ming-Jer

doi:10.1378/chest.128.1.317

Cited by 106 publications

(87 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, previous studies reported that pure or mixed GGO and lepidic dominant histologic subtype could be better predictors for EGFR mutation in lung adenocarcinoma (Hsieh et al, 2005;Yano et al, 2006;Lee et al, 2013). In our results, both lepidic dominant histologic subtype and pure or mixed GGO were related to EGFR mutation in overall patients.…”

Section: Discussionsupporting

confidence: 74%

“…Previous studies reported that increasing smoke exposure was inversely related to the rate of EGFR mutation (Kosaka et al, 2004;Hsieh et al, 2005;Shigematsu et al, 2005;Mitsudomi et al, 2006;D'Angelo et al, 2011). Thus, it has been suggested that EGFR mutations may play a key role in the development of NSCLC in patients with a low exposure to cigarette smoking.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Epidermal Growth Factor Receptor Mutations in Japanese Men with Lung Adenocarcinomas

Tomita

Ayabe²,

Chosa³

et al. 2015

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

related with never-smoker, women, adenocarcinoma and Asians (Kosaka et al., 2004;Shigematsu et al., 2005;Mitsudomi et al., 2006). Therefore it might demonstrate the role of histology, sex, lifestyle and ethnicity as variables associated with EGFR mutation. To our knowledge, however, there is only one study that focused on EGFR mutation in men and smokers (D'Angelo et al., 2011). Of great interest, they concluded that a large number of EGFR mutations are found in adenocarcinoma tumor specimen from men and people who smoked Masaki Tomita*, Takanori Ayabe, Eiichi Chosa, Katsuya Kawagoe, Kunihide Nakamura cigarettes. In the present study, we focused on the men with adenocarcinoma patients, and we examined the relationship between EGFR mutation and clinical characteristics.

show abstract

Section: Discussionsupporting

confidence: 74%

Section: Discussionmentioning

confidence: 99%

Epidermal Growth Factor Receptor Mutations in Japanese Men with Lung Adenocarcinomas

Tomita

Ayabe²,

Chosa³

et al. 2015

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…Consistent with previous reports, patients who are female, never-smokers, and who have bronchioalveolar or adenocarcinoma histology were significantly more likely to harbor mutations. [30][31][32] Smoking status was the strongest predictor of harboring an EGFR mutation.…”

Section: Discussionmentioning

confidence: 96%

Epidermal growth factor receptor mutations detected by denaturing high‐performance liquid chromatography in nonsmall cell lung cancer

Cohen

Agulnik

Ang

et al. 2010

Cancer

View full text Add to dashboard Cite

BACKGROUND:Somatic mutations in the epidermal growth factor receptor (EGFR) kinase domain are associated with sensitivity to EGFR‐tyrosine kinase inhibitors (EGFR‐TKI) in patients with nonsmall cell lung cancer (NSCLC).METHODS:The authors tested the possibility that nucleotide sequencing may be poorly suited for detection of mutations in tumor samples and found that denaturing high‐performance liquid chromatography (dHPLC) was an efficient and more sensitive method for screening.RESULTS:These results suggested that some reports based on standard DNA sequencing techniques may have underestimated mutation rates. In the present report, the authors examined the relationship between the presence and type of EGFR mutations detected by dHPLC and various clinicopathologic features of NSCLC, including response to therapy with EGFR‐TKI. Among 251 patients with advanced disease, 100 individuals received EGFR‐TKI. Those whose tumors harbored a detectable EGFR kinase mutation were much more likely to have a partial response (PR) or stable disease (SD) with EGFR‐TKI therapy than patients whose tumor contained no mutation (80% vs 35%; P = .001). Among the individual genotype subgroups, the frequency of a PR or SD was significantly different between patients with an exon 19 deletion compared with those with no detectable mutation (86% vs 35%; P < .001). Furthermore, patients whose tumors expressed an exon 19 mutant EGFR isoform exhibited a trend toward better EGFR‐TKI response (86% vs 67%; P = .171) and improved survival compared with patients whose tumors expressed an exon 21 mutation.CONCLUSIONS:Our findings warrant confirmation in large prospective trials and exploration of the biological mechanisms of the differences between mutation types. Cancer 2010. © 2010 American Cancer Society.

show abstract

“…It has been reported that EGFR mutations occured more frequently in female patients and never smokers (49,50). Yang (32) reported that the EGFR mutation rate was significantly higher in adenocarcinoma than in other types of NSCLC (21 For the above table parameters, apart from rash (p<0.01), no significant statistical differences were achieved between the mutation and nonmutation group (p>0.01).…”

Section: Discussionmentioning

confidence: 95%

EGFR mutations predict a favorable outcome for malignant pleural effusion of lung adenocarcinoma with Tarceva therapy

Guo

Wan²,

Tian³

et al. 2011

Oncol Rep

View full text Add to dashboard Cite

Abstract. The aim of the present study was to evaluate the therapeutic effects and adverse reactions of Tarceva treatment for malignant pleural effusion (MPE) caused by metastatic lung adenocarcinomas. One hundred and twenty-eight patients who failed first-line chemotherapy drug treatment were divided into a mutation and a non-mutation group according to the presence or absence of epidermal growth factor receptor (EGFR) mutations. Each patient received closed drainage combined with simple negative pressure suction after thoracoscopic talc poudrage pleurodesis and oral Tarceva treatment. Short-term and long-term clinical therapeutic effects of Tarceva were evaluated. The EGFR mutation rate in pleural metastatic tissues of lung adenocarcinoma acquired through video-assisted thoracoscopic surgery was higher compared to that in surgical resection specimens, plasma specimens and pleural effusion specimens compared to previously reported results. There were significant statistical differences in the average extubation time (p<0.01), drainage volume of pleural effusion (p<0.05), Karnofsky score and formation of encapsulated pleural effusion 4 weeks after surgery (p<0.05) between these two groups. The number of patients with mild pleural hypertrophy in the mutation group was significantly higher compared to the non-mutation group (p<0.01), while the number of patients with severe pleural hypertrophy was significantly reduced (p<0.05). There was significant statistical discrepancy between these two groups in terms of improvement of peripheral blood carcinoembryonic antigen and tissue polypeptide antigen after 4 weeks of therapy. The complete remission rate and the efficacy rate were higher in the mutation group compared to that in the non-mutation group (p<0.05). There was a longer overall survival time after Tarceva treatment in patients with EGFR mutations than those without EGFR mutation. EGFR mutations predict a favorable outcome for malignant pleural effusion of lung adenocarcinoma with Tarceva therapy. Detection of EGFR mutations may determine the responsiveness of malignant pleural effusion to Tarceva treatment.

show abstract

Female Sex and Bronchioloalveolar Pathologic Subtype Predict EGFR Mutations in Non-small Cell Lung Cancer

Cited by 106 publications

References 16 publications

Epidermal Growth Factor Receptor Mutations in Japanese Men with Lung Adenocarcinomas

Epidermal Growth Factor Receptor Mutations in Japanese Men with Lung Adenocarcinomas

Epidermal growth factor receptor mutations detected by denaturing high‐performance liquid chromatography in nonsmall cell lung cancer

EGFR mutations predict a favorable outcome for malignant pleural effusion of lung adenocarcinoma with Tarceva therapy

Contact Info

Product

Resources

About